Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $83.63 USD
Change Today +1.12 / 1.36%
Volume 588.8K
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

abiomed inc (ABMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/13/15 - $110.68
52 Week Low
10/13/14 - $21.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABIOMED INC (ABMD)

Related News

No related news articles were found.

abiomed inc (ABMD) Related Businessweek News

No Related Businessweek News Found

abiomed inc (ABMD) Details

ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company provides Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics. Further, it engages in the research, development, prototyping, and production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. The company sells its products through direct sales and clinical support personnel in the United States, Germany, France, Canada, Japan, and the United Kingdom. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

589 Employees
Last Reported Date: 05/28/15
Founded in 1981

abiomed inc (ABMD) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $537.9K
Chief Operating Officer
Total Annual Compensation: $350.4K
Vice President and General Manager of Global ...
Total Annual Compensation: $306.7K
Senior Vice President of Global Product Opera...
Total Annual Compensation: $294.6K
Total Annual Compensation: $323.3K
Compensation as of Fiscal Year 2015.

abiomed inc (ABMD) Key Developments

ABIOMED Showcases Impella(R) Technology at TCT 2015 with over 25 Presentations in the Scientific Sessions

ABIOMED, Inc. announced that there are currently over 25 presentations potentially featuring the Impella line of heart pumps, scheduled in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific meeting, scheduled from October 11 - 15, at the Moscone Convention Center in San Francisco. On the TCT show floor, at Abiomed's booth #1117 there will be daily demonstrations and opportunities for physicians to engage in hands-on simulations of the Impella platform with new simulator technology. Additionally, Abiomed anticipates the broadcast of potentially multiple live cases utilizing Impella from the participating live case sites in the main arena, coronary theater and structural heart theater in the Moscone Center. Further details concerning these live cases will be disclosed the day of the scheduled procedures, as patient status is subject to change. The schedule for Protected PCI or CHIP (Complex Higher-Risk and Indicated Patients) related TCT symposiums is below. There are additional Impella-related presentations and poster sessions anticipated at TCT.

ABIOMED Appoints Seth Bilazarian as New Vice President of Interventional Cardiology Programs

ABIOMED, Inc. announced that Seth Bilazarian, M.D. will be appointed as Vice President of Interventional Cardiology Programs, effective October 8, 2015. Dr. Bilazarian is a clinical and interventional cardiologist and has performed coronary and peripheral interventions at Lahey Clinic, Boston University Medical Center and Massachusetts General Hospital and was Director of the Cardiac Catheterization Laboratory (Cath Lab) and Chief of the Cardiovascular Steering Committee at Lawrence General. Most recently, he was the Director of Clinical Cardiology Research Program and Clinical Cardiologist at Pentucket Medical Associates, LLC. He also serves on the faculty as an instructor in medicine at Harvard Medical School, where he has taught since 1995 and is the founder and director of the community based cardiac research program in the Partner's network.

Abiomed, Inc Announces FDA Submission of Impella 2.5, Impella CP & Impella 5.0/LD Pre-Market Approval Supplements

Abiomed, Inc. announced that it has submitted U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplemental submissions requesting to expand Impella 2.5 PMA approval to all of the Impella family of devices (Impella 2.5, Impella CP® and Impella 5.0/LD). The submissions are for a set of indications related to the use of the Impella devices in patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. These submissions are proposed as a supplement to the Impella 2.5 PMA approval for high risk percutaneous coronary intervention (PCI) received on March 23, 2015, and include analysis on 415 patients from the FDA study RECOVER 1 and the U.S. Impella registry, and a relevant Impella literature review that references 692 patients in 17 clinical studies. Additionally, over 24,000 Impella patients supported by Impella devices were reviewed in a safety analysis provided using the FDA/Medical Device Reporting (MDR) database. Through its review of the supplemental submission, the FDA will ultimately render a decision concerning the safety and efficacy of the Impella CP and the Impella 5.0 in the applied-for patient populations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABMD:US $83.63 USD +1.12

ABMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hansen Medical Inc $4.21 USD -0.03
HeartWare International Inc $50.07 USD -1.43
LeMaitre Vascular Inc $12.39 USD -0.18
Spectranetics Corp/The $10.90 USD -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation ABMD Industry Range
Price/Earnings 29.2x
Price/Sales 13.5x
Price/Book 11.2x
Price/Cash Flow 27.9x
TEV/Sales 13.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABIOMED INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at